CN105748409A - Protopanoxadiol submicroemulsion preparation as well as preparation method and application thereof - Google Patents
Protopanoxadiol submicroemulsion preparation as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN105748409A CN105748409A CN201610115501.3A CN201610115501A CN105748409A CN 105748409 A CN105748409 A CN 105748409A CN 201610115501 A CN201610115501 A CN 201610115501A CN 105748409 A CN105748409 A CN 105748409A
- Authority
- CN
- China
- Prior art keywords
- preparation
- oil
- protopanoxadiol
- emulsifying agent
- submicron emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 64
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 20
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 8
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 6
- 230000004663 cell proliferation Effects 0.000 claims abstract description 5
- 239000000839 emulsion Substances 0.000 claims description 66
- 239000003921 oil Substances 0.000 claims description 24
- 235000019198 oils Nutrition 0.000 claims description 24
- 239000012071 phase Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 238000000265 homogenisation Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 210000002798 bone marrow cell Anatomy 0.000 claims description 5
- 235000019483 Peanut oil Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 210000003022 colostrum Anatomy 0.000 claims description 4
- 235000021277 colostrum Nutrition 0.000 claims description 4
- 239000006185 dispersion Substances 0.000 claims description 4
- 238000004945 emulsification Methods 0.000 claims description 4
- 239000000312 peanut oil Substances 0.000 claims description 4
- 210000001938 protoplast Anatomy 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 3
- 239000010775 animal oil Substances 0.000 claims description 3
- 210000002969 egg yolk Anatomy 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 229940067606 lecithin Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical group C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 230000005757 colony formation Effects 0.000 claims description 2
- 230000000925 erythroid effect Effects 0.000 claims description 2
- 230000011132 hemopoiesis Effects 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 239000002245 particle Substances 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 206010028980 Neoplasm Diseases 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 239000007957 coemulsifier Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 230000001629 suppression Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003394 haemopoietic effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 238000013019 agitation Methods 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000001804 emulsifying effect Effects 0.000 description 3
- 239000004973 liquid crystal related substance Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000002960 bfu-e Anatomy 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 210000003013 erythroid precursor cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 125000003827 glycol group Chemical group 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical group CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- PYXFVCFISTUSOO-HKUCOEKDSA-N (20S)-protopanaxadiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@@](C)(O)CCC=C(C)C)[C@H]4[C@H](O)C[C@@H]3[C@]21C PYXFVCFISTUSOO-HKUCOEKDSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GHWSMQHJFMAATF-DSHMRAQASA-N 20(S)-protopanaxadiol Natural products CC(=CCC[C@@](O)(CO)[C@H]1CC[C@]2(C)[C@@H]1CC[C@H]3[C@@]2(C)CC[C@H]4C(C)(C)[C@@H](O)CC[C@]34CO)C GHWSMQHJFMAATF-DSHMRAQASA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- LKUNXBRZDFMZOK-GFCCVEGCSA-N Capric acid monoglyceride Natural products CCCCCCCCCC(=O)OC[C@H](O)CO LKUNXBRZDFMZOK-GFCCVEGCSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- PYXFVCFISTUSOO-UHFFFAOYSA-N betulafolienetriol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC(C(C)(O)CCC=C(C)C)C4C(O)CC3C21C PYXFVCFISTUSOO-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 description 1
- 229940031016 ethyl linoleate Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- DKVBOUDTNWVDEP-NJCHZNEYSA-N teicoplanin aglycone Chemical compound N([C@H](C(N[C@@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)OC=1C=C3C=C(C=1O)OC1=CC=C(C=C1Cl)C[C@H](C(=O)N1)NC([C@H](N)C=4C=C(O5)C(O)=CC=4)=O)C(=O)[C@@H]2NC(=O)[C@@H]3NC(=O)[C@@H]1C1=CC5=CC(O)=C1 DKVBOUDTNWVDEP-NJCHZNEYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a protopanoxadiol submicroemulsion preparation and a preparation method thereof. The protopanoxadiol submicroemulsion preparation comprises protopanoxadiol, oil, an emulsifier and a co-emulsifier, average particle size of the protopanoxadiol submicroemulsion preparation is 110-130nm, and Zeta potential ranges from -40mV to -20mV. The invention also provides an application of the protopanoxadiol submicroemulsion preparation in preparation of a medicine with the effects of promoting hematopoietic cell proliferation and alleviating bone marrow inhibiting effect caused by tumour treatment.
Description
Technical field
The present invention relates to a kind of protopanoxadiol Submicron Emulsion preparation and its production and use, belong to pharmaceutical preparation neck
Territory.
Background technology
Protopanoxadiol (PPD) is diol type ginsengenin, is mainly derived from the Araliaceaes such as ginseng, American Ginseng, pseudo-ginseng
Plant.It is the aglycon of glycol group ginsenoside, is also glycol group ginsenoside end product after microorganism glycolysis.Research table
The sodium channel that bright PPD has suppression kinds of tumors growth, antidepression, activation chloride channel, suppression to be activated depolarizes, suppression people
Many activity such as the growth of embryonic kidney cell HEK-293 cell and growth of H. pylori.Meanwhile, cerebral damage is had by PPD
Protective effect.
PPD is lipophilic compound, and in water, dissolubility is poor, and oral administration biaavailability is low, and the half-life is short.Need protoplast
The preparation of ginseng glycol carries out studying to improve bioavilability.The researchs such as hair Jingjing are prepared for PPD dry suspensoid agent, and this formulation is improved
Drug absorption, and do not affected by food, particle is big at intestines and stomach distribution areas, absorbs fast, and bioavilability is carried
Height (sees a mao Jingjing, Zhang Tong, Wang Bing etc..The prescription of 20 (S)-protopanoxadiol dry suspensoid agents and preliminary quality research.Middle one-tenth
Medicine, 2013,34 (9): 1680-1684).Jin Shengxuan etc. are prepared for PPD liposome for intravenous injection, pass to realizing targeting
Medicine, plays antitumor action and (sees Jin Shengxuan, Lei Rongjian, Sun Jingyun.HPLC measures containing of 20 (s)-Protopanaxadiol liposome
Amount and envelop rate.Nanjing University of Traditional Chinese Medicine's journal, 2009,25 (3): 197-198).Jin Xin etc. are prepared for the protoplast of PPD and join lipid
Cubic liquid crystal nanoparticle, lipid cubic liquid crystal by polar lipid in aqueous environment by adsorb quantitative water formed have special
The gellike of internal structure cube skeleton structure mutually, has stronger adhesiveness, thus promotes that medicine cross-film absorbs.Preparation is set up
After side's liquid crystal, adding the medicine holdup time in vivo, Relative oral bioavailability is 1.66 times of bulk drug and (sees gold
Prosperous, Zhang Zhenhai, Sun E etc., protopanoxadiol lipid-based cubic liquid crystalline nanoparticle pharmacokinetic studies in rat body.Chinese medicine
Magazine, 2013,38 (2): 263-268).Drug carrier passed by emulsion can increase solubility and the stability of insoluble drug, oil
Phase and emulsifying agent can degrade and absorb in vivo, and stable in properties does not produce superman's body standard osmotic pressure after intravenous.Warp of the present invention
Patent consulting and literature search, the most not yet find PPD is prepared as emulsion for injection, carry out the report of antitumor research.
Summary of the invention
It is an object of the present invention to provide a kind of protopanoxadiol Submicron Emulsion preparation；
Second object of the present invention is to provide the preparation method of this protopanoxadiol Submicron Emulsion preparation；
Third object of the present invention is to provide the Submicron Emulsion preparation prepared by protopanoxadiol and the present invention in preparation
There is the application in the medicine promoting hematopoietic cell proliferation, alleviation bone marrow inhibition.
A kind of protopanoxadiol Submicron Emulsion preparation, including protopanoxadiol, oil, emulsifying agent, assistant for emulsifying agent, its average grain diameter
Being 110～130nm, Zeta potential is-20～-40mV.This protopanoxadiol Submicron Emulsion preparation is through high pressure, centrifugal, dilution process
The most moderately good, in 4,20,30 DEG C of stability tests 4 months, have good stability.
In some embodiments, described protopanoxadiol content is 0.1-0.5%, oil phase content 10-30%, emulsifying agent
With assistant for emulsifying agent content 3-4%；Preferably, emulsifying agent is 2:1～2 with the ratio of assistant for emulsifying agent；It is further preferred that oil phase contains
Amount is 10%, and emulsifying agent is 2:1.5 with the ratio of assistant for emulsifying agent.
In some embodiments, described grease separation is from vegetable oil, animal oil, mineral oil or artificial oil；Described plant grease separation
Any one or a few in soybean oil, corn oil, peanut oil, olive oil, castor oil, palm oil；Described animal oil is selected from
Fish oil or oleic acid；Described mineral oil is selected from any one or a few in aliphatic hydrocarbon, cerul hydrocarbon, aromatic hydrocarbon or paraffin oil；Described
Artificial oil is selected from linoleic acid, ethyl oleate, rilanit special, hydrogenated groundnut, cotmar, ethyl linoleate, self-emulsifying
Any one or a few in monostearate, pungent/glycerol decanoate, isopropyl myristate or triethylglycerides；Further
Preferably, described oil is soybean oil or peanut oil.
In some embodiments, described emulsifying agent is selected from Fabaceous Lecithin, yolk phospholipid, phosphatidyl-ethanolamine, serine phosphorus
Any one or a few in fat, lipositol, phosphatidic acid；The most described emulsifying agent is egg yolk lecithin or soybean ovum phosphorus
Fat.
In some embodiments, described assistant for emulsifying agent is selected from poloxamer (F68) or solutol.
The preparation method that present invention also offers described protopanoxadiol Submicron Emulsion preparation comprises the steps:
Step 1, the preparation of oil phase: add emulsifying agent and effective dose PPD in appropriate oil, dispersion obtains oil phase；
Step 2, the preparation of aqueous phase: qs glycerin, assistant for emulsifying agent are dissolved in suitable quantity of water, make aqueous phase；
Step 3, just emulsification: under the conditions of 60～70 DEG C, oil phase is added aqueous phase, make colostrum；
Step 4, homogeneous: taking the primary emulsion of step 3 preparation, homogeneous, emulsification, is 110～130nm to emulsion droplet average grain diameter；
Step 5, filling, sterilizing.
In some embodiments, step 3 carries out ultrasonically treated after oil phase adds aqueous phase, and ultrasonic time is 5-60min；
Step 4 homogeneous is carried out in high pressure homogenizer, and homogenization pressure is 500-2000bar, and cycle-index is 5-20 time.Preferably, super
The sound time is 10-20min；Step 4 homogenization pressure is 1000-2000bar, and cycle-index is 5-15 time.It is further preferred that it is super
The sound time is 10min；Homogenization pressure is 2000bar, and cycle of higher pressure number of times is 10 times.
The present invention also provides for protopanoxadiol and has the bone promoting hematopoietic cell proliferation, alleviating oncotherapy generation in preparation
Application in the medicine of marrow inhibitory action.
Internal experiment in vitro all prove protopanoxadiol emulsion for injection can be obviously promoted bone marrow cell grain system (CFU-GM),
Red system (CFU-E/BFU-E) hematopoietic progenitor population generates.Show that protopanoxadiol emulsion for injection has promotion hematopoietic cell
The effect of the bone marrow suppression that propagation, alleviation oncotherapy produce.
Accompanying drawing explanation
Fig. 1 PPD Submicron Emulsion formulation aesthetics form
Form under Fig. 2 PPD Submicron Emulsion preparation transmission electron microscope
Specific embodiment mode
Embodiment 1
Prescription:
Embodiment 2
Embodiment 3
Prescription:
Embodiment 4
Prescription:
Embodiment 5
Prescription:
Embodiment 6
The preparation method of the arbitrary prescription of embodiment 1～5: oil phase (soybean oil or peanut oil) is stirred in 80 DEG C and adds breast
Agent, high speed dispersion, to becoming settled solution, then adds protopanoxadiol at 60 DEG C, and high speed dispersion uniformly obtains oil phase；Separately
Adding 20ml glycerine and assistant for emulsifying agent in 800ml water, 60 DEG C are uniformly mixing to obtain aqueous phase.Under 60 DEG C of high-speed stirred, by oil
Slowly it is added drop-wise to aqueous phase mutually, continues ultrasonic agitation 10 minutes, be settled to 1000ml.By colostrum through high-pressure homogeneous 2000bar pressure
Circulate 10 times, filling, sterilizing, both.
The Submicron Emulsion preparation physical parameter that embodiment 1～5 prescription is prepared by the present embodiment method
Embodiment 7
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: the ultrasonic agitation time
It it is 15 minutes.
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 115～125nm, and Zeta potential is-30
～-40mV.
Embodiment 8
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: the ultrasonic agitation time
It it is 20 minutes.
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 115～125nm, and Zeta potential is-30
～-40mV.
Embodiment 9
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: high-pressure homogeneous pressure
For 1000bar, high-pressure homogeneous cycle-index is 10.
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 115～125nm, and Zeta potential is-30
～-40mV.
Embodiment 10
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: high-pressure homogeneous pressure
For 700bar, high-pressure homogeneous cycle-index is 15.
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 115～125nm, and Zeta potential is-30
～-40mV.
Embodiment 11
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: first emulsifying temperature is
70℃。
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 115～125nm, and Zeta potential is-30
～-40mV.
Embodiment 12
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: first emulsifying temperature is
40℃。
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 230～240nm.
Embodiment 13
The preparation method of the arbitrary prescription of embodiment 1～5, substantially the same manner as Example 6, difference is: first emulsifying temperature is
80℃。
Its average grain diameter of Submicron Emulsion preparation that the present embodiment method prepares is 240～250nm.
Submicron Emulsion preparation stability is investigated:
Test Submicron Emulsion preparation is the Submicron Emulsion preparation that embodiment 1 prescription is prepared by embodiment 6 preparation method.
The sign of Submicron Emulsion:
Proterties: outward appearance presents dispersed, milky Submicron Emulsion preparation, weak blue fluorescence (see Fig. 1) seen from bottle wall.
PH value: PPD Submicron Emulsion between pH value 8.2-8.4, has prepared unpasteurized PPD Submicron Emulsion pH when being prepared as colostrum
Value is between 7.9-8.0, and the PPD Submicron Emulsion pH value after sterilizing is between 7.0-7.2.
Submicron Emulsion morphologic observation: take the appropriate distilled water diluting of Submicron Emulsion to debita spissitudo, dripped by micro emulsion on copper mesh, uses
2% phosphotungstic acid negative staining 1min, with observing the form of emulsion droplet, for black even scattered spherical (see Fig. 2) under transmission electron microscope.
Stability:
1, the autoclaving impact on Submicron Emulsion
Take with a collection of Submicron Emulsion, be divided into 2 parts, and a pressure sterilizing (105 DEG C, 45min；115 DEG C, 30min and 121 DEG C,
15min), a without pressure sterilizing, observe the outward appearance of 2 parts of Submicron Emulsions, compare the change of particle diameter, current potential and medicament contg simultaneously
Change.The results are shown in Table 1.
The impact on PPD Submicron Emulsion of table 1 autoclaving
Result shows PPD Submicron Emulsion stable in physicochemical property after autoclaving.
2, dewatering ability
By Submicron Emulsion three batches, 3500rmp, centrifugal 20min, seen whether that medicine crystal grain separates out, mensuration particle diameter, current potential,
Medicament contg.The results are shown in Table 2.
The dewatering ability of table 2 PPD Submicron Emulsion
The dewatering ability of result display PPD Submicron Emulsion is good.
3, dilution stability
By Submicron Emulsion three batches, after diluting 10,50,100,200,500,1000,2000 times respectively, see whether that medicine is brilliant
Size separation goes out, and measures particle diameter, current potential.The results are shown in Table 3.
The dilution stability of table 3 PPD Submicron Emulsion
| Multiple | Particle diameter (nm) | PDI | Current potential (-mV) |
| 0 | 119.7±0.9 | 0.142±0.022 | -35.6±1.6 |
| 10 | 132.9±0.8 | 0.198±0.019 | -33.5±0.3 |
| 50 | 120.1±1.3 | 0.145±0.021 | -33.4±1.0 |
| 100 | 119.7±0.9 | 0.142±0.022 | -35.6±1.6 |
| 200 | 120.6±1.0 | 0.143±0.009 | -38.8±3.9 |
| 500 | 118.5±0.7 | 0.149±0.024 | -37.6±0.6 |
| 1000 | 120.7±0.3 | 0.154±0.009 | -28.1±0.8 |
| 2000 | 124.4±0.2 | 0.203±0.026 | -23.4±3.7 |
Result display dilution is stable, dilutes 2000 times of change of size still less than 5%.
4, PPD Submicron Emulsion places the stability of 1,2,3,4,5 months respectively
Table 41 month shelf-stability of PPD Submicron Emulsion
Table 52 months shelf-stabilities of PPD Submicron Emulsion
Table 63 months shelf-stabilities of PPD Submicron Emulsion
Table 74 months shelf-stabilities of PPD Submicron Emulsion
PPD Submicron Emulsion preparation prepared by the present invention, respectively at 4,20,30 DEG C of stability tests 4 months, has good stability.
The impact on chemotherapy mouse hematopoetic cell of the Submicron Emulsion preparation
1, the external dosing of protopanoxadiol emulsion for injection is to bone marrow suppression bone marrow cells in mice grain system (CFU-GM), red system
(CFU-E/BFU-E) impact that hematopoietic progenitor population generates.
After experiment uses endoxan 200mg/kg, modeling of lumbar injection, modeling three days, extracting marrow cell collects
Fall to cultivating, in cultivating system, add the medicine of variable concentrations simultaneously.The results are shown in Table 8.
Protopanoxadiol emulsion for injection can be obviously promoted three kinds of HPCs increasings in vitro as can be seen from the results
Growing, colony productivity is obviously higher than model group (P < 0.05 or 0.01).
The impact on bone marrow suppression mouse hemopoietic progenitor population number of the table 8 protopanoxadiol emulsion for injection
Compare with model comparison*P < 0.05,**P < 0.01,***P<0.001
2, in protopanoxadiol emulsion for injection body, dosing is thin to bone marrow suppression bone marrow cells in mice grain system, erythroid hematopoiesis ancestral
The impact of born of the same parents' colony formation.
Experimental day intraperitoneal injection of cyclophosphamide (CP) modeling, after modeling, the intravenous injection immediately of administration group gives protoplast and joins two
Alcohol emulsion for injection medicine, Normal group and model group give the distilled water of same volume, be administered volume and be 0.2ml/10g,
Successive administration 7 days, 7d often group takes 3 and carries out HPC cultivation the most upon administration, within the 1st, 3,5,7 day after modeling, takes
Blood surveys routine blood test.
1. Colony cultivation result: result can be seen that the protopanoxadiol emulsion for injection of various dose is little from following table
Three kinds of proliferation of hematopoietic progenitors can be obviously promoted in mouse body；
The impact on three kinds of proliferation of hematopoietic progenitors of mouse of the table 9 protopanoxadiol emulsion for injection
* P < 0.05, * * P < 0.01, * * * P < 0.001 is compared with model comparison
2. routine blood test result: from following table, the 7th day 75 and 150mg/kg dosage group murine interleukins after administration
(WBC) raise clearly.
Table 10 routine blood test measurement result
| Basis | 3rd day | 5th day | 7th day | |
| Normal group | 4.43±1.75 | 6.92±0.59 | 7.10±0.76 | 8.05±1.44 |
| Model group | 4.43±1.73 | 2.17±0.33 | 1.90±0.37 | 5.17±0.37 |
| 75mg/kg group | 4.57±2.19 | 1.87±0.47 | 1.89±0.81 | 19.24±5.16* |
| 150mg/kg group | 4.60±2.30 | 2.17±0.34 | 1.71±0.37 | 21.86±2.25*** |
* P < 0.05, * * P < 0.01, * * * P < 0.001 is compared with model comparison.
Claims (10)
1. a protopanoxadiol Submicron Emulsion preparation, it is characterised in that described Submicron Emulsion preparation includes protopanoxadiol, oil, breast
Agent, assistant for emulsifying agent, its average grain diameter is 110～130nm, and Zeta potential is-20～-40mV.
2. preparation as claimed in claim 1, it is characterised in that in described Submicron Emulsion preparation, each component content is: protoplast joins two
Alcohol 0.1-0.5%, oil 10-30%, emulsifying agent and assistant for emulsifying agent 3-4%.
3. preparation as claimed in claim 2, it is characterised in that described oil content is 10～15%, emulsifying agent and assistant for emulsifying agent
Ratio be 2:1～2.
4. preparation as claimed in claim 1, it is characterised in that described grease separation is from vegetable oil, animal oil, mineral oil or synthesis
Oil；Described emulsifying agent is in Fabaceous Lecithin, yolk phospholipid, phosphatidyl-ethanolamine, serinephosphatide, lipositol, phosphatidic acid
Any one or a few；Described assistant for emulsifying agent is selected from poloxamer or solutol.
5. preparation as claimed in claim 1, it is characterised in that described vegetable oil is soybean oil or peanut oil；Described emulsifying agent
For Fabaceous Lecithin or yolk phospholipid.
6. the preparation method of protopanoxadiol Submicron Emulsion preparation as described in any one of claim 1-5, it is characterised in that described side
Method comprises the steps:
Step 1, the preparation of oil phase: add emulsifying agent and effective dose protopanoxadiol in appropriate oil, dispersion obtains oil phase；
Step 2, the preparation of aqueous phase: qs glycerin, assistant for emulsifying agent are dissolved in suitable quantity of water, make aqueous phase；
Step 3, just emulsification: under the conditions of 60～70 DEG C, oil phase is added aqueous phase, make colostrum；
Step 4, homogeneous: taking the primary emulsion of step 3 preparation, homogeneous, emulsification, is 110～130nm to emulsion droplet average grain diameter；
Step 5, filling, sterilizing.
7. method as claimed in claim 6, it is characterised in that step 3 carries out ultrasonically treated after oil phase adds aqueous phase, ultrasonic
Time is 5-60min；Step 4 homogenization pressure is 500-2000bar, and cycle-index is 5-20 time.
8. method as claimed in claim 7, it is characterised in that ultrasonic time is 10-20min；Homogenization pressure is 1000-
2000bar, cycle-index is 5-15 time；Preferably, ultrasonic time is 10min；Homogenization pressure is 2000bar, cycle of higher pressure time
Number is 10 times.
9. the protopanoxadiol Submicron Emulsion preparation that as claimed in claim 6 prepared by method promotes hematopoietic cell proliferation or slow in preparation
Solve the application in the medicine of the bone marrow inhibition that oncotherapy produces；Preferably facilitate bone marrow cell grain system and/or erythroid hematopoiesis
Progenitor population generates.
10. protopanoxadiol promotes hematopoietic cell proliferation in preparation or alleviates the medicine of the bone marrow inhibition that oncotherapy produces
In application；Preferably facilitate bone marrow cell grain system and/or hemopoietic progenitor cell of red blood cell line colony formation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610115501.3A CN105748409A (en) | 2016-03-01 | 2016-03-01 | Protopanoxadiol submicroemulsion preparation as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610115501.3A CN105748409A (en) | 2016-03-01 | 2016-03-01 | Protopanoxadiol submicroemulsion preparation as well as preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105748409A true CN105748409A (en) | 2016-07-13 |
Family
ID=56332203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610115501.3A Pending CN105748409A (en) | 2016-03-01 | 2016-03-01 | Protopanoxadiol submicroemulsion preparation as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105748409A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110623926A (en) * | 2019-10-31 | 2019-12-31 | 沈阳药科大学 | Panaxatriol supersaturated self-microemulsion and preparation method thereof |
| CN112263585A (en) * | 2020-11-04 | 2021-01-26 | 复旦大学附属妇产科医院 | Application of protopanoxadiol PPD in preparing medicine for treating infertility and abortion |
| CN114425038A (en) * | 2022-01-27 | 2022-05-03 | 沈阳信康药物研究有限公司 | 20(S) -PPD liposome emulsion complex oral administration preparation and preparation method and application thereof |
| CN114831935A (en) * | 2022-05-18 | 2022-08-02 | 沈阳信康药物研究有限公司 | Sterile 20(S) -PPD oral liquid preparation capable of being administrated by nasal feeding and preparation method and application thereof |
-
2016
- 2016-03-01 CN CN201610115501.3A patent/CN105748409A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110623926A (en) * | 2019-10-31 | 2019-12-31 | 沈阳药科大学 | Panaxatriol supersaturated self-microemulsion and preparation method thereof |
| CN110623926B (en) * | 2019-10-31 | 2022-05-20 | 沈阳药科大学 | Panaxatriol supersaturated self-microemulsion and preparation method thereof |
| CN112263585A (en) * | 2020-11-04 | 2021-01-26 | 复旦大学附属妇产科医院 | Application of protopanoxadiol PPD in preparing medicine for treating infertility and abortion |
| CN114425038A (en) * | 2022-01-27 | 2022-05-03 | 沈阳信康药物研究有限公司 | 20(S) -PPD liposome emulsion complex oral administration preparation and preparation method and application thereof |
| CN114425038B (en) * | 2022-01-27 | 2023-03-10 | 沈阳信康药物研究有限公司 | 20 (S) -PPD liposome emulsion complex oral administration preparation and preparation method and application thereof |
| CN114831935A (en) * | 2022-05-18 | 2022-08-02 | 沈阳信康药物研究有限公司 | Sterile 20(S) -PPD oral liquid preparation capable of being administrated by nasal feeding and preparation method and application thereof |
| CN114831935B (en) * | 2022-05-18 | 2023-04-07 | 沈阳信康药物研究有限公司 | Sterile 20 (S) -PPD oral liquid preparation capable of being administrated by nasal feeding and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2194226C (en) | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same | |
| CN100569294C (en) | A kind of used for intravenous injection high stable long-circulation fat fat breast carrying medicine | |
| CN104427977B (en) | Depot formulations of local anesthetic and preparation method thereof | |
| CN101396343B (en) | Paclitaxel submicron emulsion using lipid composite as middle carrier | |
| CN106456541A (en) | Compositions of nanoemulsion delivery systems | |
| CN105748409A (en) | Protopanoxadiol submicroemulsion preparation as well as preparation method and application thereof | |
| CN102686217B (en) | Submicro emulsion of paclitaxel using steroid complex as intermediate carrier | |
| CN101909614A (en) | Nanodispersion | |
| CN101244053B (en) | Novel dispersed system with docetaxel as main component | |
| CN100496609C (en) | Stable liposome composition | |
| CN101829052B (en) | Self-emulsifying preparation of taxane compound and preparation method thereof | |
| CN108159055A (en) | Treat long-acting delivery system, preparation method and the application of breast cancer | |
| CN114796110A (en) | Insoluble drug concentrated solution without ethanol and micelle solution prepared from insoluble drug concentrated solution | |
| CN102552137B (en) | Triptolide fat emulsion injection and preparation method thereof | |
| CN103405385A (en) | Temozolomide intravenous injection fat emulsion and preparation method thereof | |
| JPH10510267A (en) | Emulsion suitable for administration of sphingolipid and use thereof | |
| CN100375621C (en) | Vinorelbine liposome micro ball injection and its prepn | |
| DK173596B1 (en) | Emulsion for parenteral administration | |
| CN101322688B (en) | Flumazenil oil-in-water emulsion for vein and preparation thereof | |
| CN100515389C (en) | Medicinal emulsion adapted for difficultly soluble medicine and method for preparing the same | |
| CN105832744B (en) | A kind of Alprostadil freeze-dried emulsion composition of injection | |
| TW201642834A (en) | Injecting emulsion of protopanaxadiol and preparation method thereof | |
| CN113456592A (en) | Antiseptic and anti-inflammatory liposome and preparation method thereof | |
| CN100569226C (en) | A kind of long-cycled lipid emulsion profofol preparation | |
| CN102228431A (en) | Self-emulsified medicinal composition for taxane compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20170105 Address after: 100044 Beijing city Haidian District Shangyuan Village Hospital No. 3 east 5 Building No. 142 Applicant after: Xu Qingtong Address before: 100085 Zhongguancun biological medicine Park, Haidian District, Beijing, No. 5 on the road to open up B-201 Applicant before: Zhao Shumin |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160713 |